Figure 3. Secondary End Points.

Analyzed in the primary analysis population, defined as all randomized patients meeting the study entry criteria and with no protocol deviations affecting the treatment efficacy. Patients were followed up for a median (IQR) of 364 days (364-371) in the half-dose group and 364 days (360-377) in the stable-dose group. Variables displayed based on clinical relevance. PROMIS indicates Patient-Reported Outcomes Measurement Information 20-item Short Form Physical Function. Boxes mark first and third quartiles, the band inside the box is the second quartile (the median), while the whiskers indicate the highest and lowest values within 1.5 × the interquartile range (IQR). Dots denote individual patients (outliers).

^aSee footnote c under Table 1 for scale descriptions.

^bPROMIS assesses the ability to perform basic and instrumental activities of daily living. The total score is translated into a T score with a mean (SD) of 50 (10). A score of 50 equals the average for the general US population.

^cThe van der Heijde–modified Sharp scoring method assesses erosions in 16 joints of each hand and 6 joints of each foot, and the erosions are given a score of 1 to 5. Joint space narrowing is assessed in 15 joints for each hand and 6 joints for each foot. This gives scores for erosions on a scale from 0 to 280 and joint space narrowing on a scale from 0 to 168, thus the total van der Heijde–modified Sharp score ranges from 0 to 448, with higher scores indicating greater joint damage. A good radiographic outcome is commonly defined as no progression.

^dDisease Activity Score at the visit before a flare occurred, at the flare visit, and at visits after flare in the half-dose arm in those with all components available to calculate DAS.